Antipsychotics and Tetrabenazine: More Rapid Progression of HD?

Posted October 1, 2015 by LaVonne Goodman, M.D.

In a recent publication in the Journal for Huntington's Disease, Tedroff and collaborators report that antidopaminergic (antipsychotic and tetrabenazine) drugs were associated with more rapid progression of Huntington's disease. Any study showing a factor associated with more rapid progression is important. However the question remains whether these medications "caused" the more rapid progression, or whether those on these medications had a more severe type of HD that would have progressed more rapidly with or without the medications.

What is the take home message from this study for individuals with HD who are taking these drugs?  

Pridopidine and the Hope for HD Neuroprotection

Posted June 25, 2015 by LaVonne Goodman, M.D.

In a new laboratory study from Italy, investigators have reported a very exciting result for Huntington's (HD).  Pridopidine, the drug presently in clinical trial for HD was shown -- not just to treat motor symptoms -- but also to provide neuroprotective benefit in a genetic mouse model of Huntington's.

Though the important pridopidine human study, the PRIDE-HD trial has another year to be completed, and more time needed to complete analysis, this mouse study suggests we might get more than symptom benefit from this new drug.  Exciting indeed that it might give neuroprotection too.
HDBuzz content loading
Treatment Guidelines for Huntington's: Who needs them?

Posted by LaVonne Goodman M.D.

During my years as an internal medicine physician, I have used standard of care guidelines for my patients with conditions like diabetes and heart disease. Guidelines are developed by experts in each disease who translate clinical trial evidence and/or expert experience into recommended care patterns for use in medical offices or at the bedside. When followed, guidelines have been central to improving the quality of care provided by all physicians whether they are specialists or generalists.   


To comment on this article or contact HDDW for any other reason, please email us.

© 2007 HDDW. All Rights Reserved.